Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Modano who wrote (664)	5/27/1998 8:05:00 PM
From: Modano	Read Replies (2) of 965

I found this great post on the Yahoo thread. Good luck everyone. Modano : ) csny57 (old/M/Mars) May 27 1998 7:25PM EDT Eric Hecht over at Merrill this afternoon said,"We expect the panel to recommend approval for either moderate to severe Crohn's, or Crohn's fistulae or possibly both. The broader label of both indications would send the shares higher. A recommendation of approval for fistulae only would be in line to slightly below street expectations, and the shares would likely be unaffected. A recommendation to not approve the drug would have a definite negative impact on the shares; however, we view this outcome as improbable. Our EPS estimates remain unchanged. The stock remain Buy rated with a 12 month price objective of $70 per share, based upon a 35 multiple applied to our year 2000 EPS estimate of $2.00". Lets only hope so!! Chris

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next